Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.8 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.7 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.7 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.41NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.90 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.90 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.30NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.1.1.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.87NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.87NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.16 (Gamma)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
P.1.16 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.10.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.10.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.5 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.4.5 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
AY.34.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.34.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.2.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.4.2.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.2.16NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.2.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.3.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
JN.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LV.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
LV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.23NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
HK.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GE.1.2.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
GE.1.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.2.2.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
JN.2.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JC.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
JC.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.1.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.7NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AD.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-18756.6US
AD.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.201NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.201NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.309NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used